158 related articles for article (PubMed ID: 35257740)
1. A Randomized, Controlled Trial to Investigate the Efficacy of Nebulized Poractant Alfa in Premature Babies with Respiratory Distress Syndrome.
Dani C; Talosi G; Piccinno A; Ginocchio VM; Balla G; Lavizzari A; Stranak Z; Gitto E; Martinelli S; Plavka R; Krolak-Olejnik B; Lista G; Spedicato F; Ciurlia G; Santoro D; Sweet D;
J Pediatr; 2022 Jul; 246():40-47.e5. PubMed ID: 35257740
[TBL] [Abstract][Full Text] [Related]
2. Nebulized Poractant Alfa Reduces the Risk of Respiratory Failure at 72 Hours in Spontaneously Breathing Surfactant-Deficient Newborn Piglets.
Rey-Santano C; Mielgo VE; Gomez-Solaetxe MA; Bianco F; Salomone F; Loureiro B
Crit Care Med; 2020 Jun; 48(6):e523-e531. PubMed ID: 32301841
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
[TBL] [Abstract][Full Text] [Related]
4. Synthetic Surfactant CHF5633 Compared with Poractant Alfa in the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial.
Ramanathan R; Biniwale M; Sekar K; Hanna N; Golombek S; Bhatia J; Naylor M; Fabbri L; Varoli G; Santoro D; Del Buono D; Piccinno A; Dammann CE
J Pediatr; 2020 Oct; 225():90-96.e1. PubMed ID: 32553868
[TBL] [Abstract][Full Text] [Related]
5. From bench to bedside: in vitro and in vivo evaluation of a neonate-focused nebulized surfactant delivery strategy.
Bianco F; Ricci F; Catozzi C; Murgia X; Schlun M; Bucholski A; Hetzer U; Bonelli S; Lombardini M; Pasini E; Nutini M; Pertile M; Minocchieri S; Simonato M; Rosa B; Pieraccini G; Moneti G; Lorenzini L; Catinella S; Villetti G; Civelli M; Pioselli B; Cogo P; Carnielli V; Dani C; Salomone F
Respir Res; 2019 Jul; 20(1):134. PubMed ID: 31266508
[TBL] [Abstract][Full Text] [Related]
6. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
Fujii A; Allen R; Doros G; O'Brien S
J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
[TBL] [Abstract][Full Text] [Related]
7. Nebulization of High-Dose Poractant Alfa in Newborn Piglets on Nasal Continuous Positive Airway Pressure Yields Therapeutic Lung Doses of Phospholipids.
Nord A; Bianco F; Salomone F; Ricci F; Schlun M; Linner R; Cunha-Goncalves D
Am J Perinatol; 2022 Jul; 39(9):1001-1007. PubMed ID: 33242911
[TBL] [Abstract][Full Text] [Related]
8. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome.
Fujii AM; Patel SM; Allen R; Doros G; Guo CY; Testa S
J Perinatol; 2010 Oct; 30(10):665-70. PubMed ID: 20336076
[TBL] [Abstract][Full Text] [Related]
9. Dose-Response Study on Surfactant Nebulization Therapy During Nasal Continuous Positive Airway Pressure Ventilation in Spontaneously Breathing Surfactant-Deficient Newborn Piglets.
Rey-Santano C; Mielgo V; Gomez-Solaetxe MA; Ricci F; Bianco F; Salomone F; Loureiro B
Pediatr Crit Care Med; 2020 Jul; 21(7):e456-e466. PubMed ID: 32195907
[TBL] [Abstract][Full Text] [Related]
10. Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome.
Kadıoğlu Şimşek G; Kanmaz Kutman HG; Canpolat FE; Oğuz ŞS
Clin Respir J; 2020 Mar; 14(3):285-290. PubMed ID: 31814293
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study.
Jeon GW; Oh M; Sin JB
Yonsei Med J; 2015 Mar; 56(2):433-9. PubMed ID: 25683992
[TBL] [Abstract][Full Text] [Related]
12. Nebulised surfactant to reduce severity of respiratory distress: a blinded, parallel, randomised controlled trial.
Minocchieri S; Berry CA; Pillow JJ;
Arch Dis Child Fetal Neonatal Ed; 2019 May; 104(3):F313-F319. PubMed ID: 30049729
[TBL] [Abstract][Full Text] [Related]
13. The OPTIMIST-A trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation.
Dargaville PA; Kamlin CO; De Paoli AG; Carlin JB; Orsini F; Soll RF; Davis PG
BMC Pediatr; 2014 Aug; 14():213. PubMed ID: 25164872
[TBL] [Abstract][Full Text] [Related]
14. Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial.
Dargaville PA; Kamlin COF; Orsini F; Wang X; De Paoli AG; Kanmaz Kutman HG; Cetinkaya M; Kornhauser-Cerar L; Derrick M; Özkan H; Hulzebos CV; Schmölzer GM; Aiyappan A; Lemyre B; Kuo S; Rajadurai VS; O'Shea J; Biniwale M; Ramanathan R; Kushnir A; Bader D; Thomas MR; Chakraborty M; Buksh MJ; Bhatia R; Sullivan CL; Shinwell ES; Dyson A; Barker DP; Kugelman A; Donovan TJ; Tauscher MK; Murthy V; Ali SKM; Yossuck P; Clark HW; Soll RF; Carlin JB; Davis PG;
JAMA; 2021 Dec; 326(24):2478-2487. PubMed ID: 34902013
[TBL] [Abstract][Full Text] [Related]
15. Surfactant nebulization therapy during NIPPV ventilation in surfactant-deficient newborn piglets.
Rey-Santano C; Mielgo V; Gastiasoro E; Bianco F; Salomone F; Gomez-Solaetxe MA
Pediatr Pulmonol; 2021 Jul; 56(7):2125-2135. PubMed ID: 33960742
[TBL] [Abstract][Full Text] [Related]
16. The short-term outcome of a large cohort of very preterm infants treated with poractant alfa (Curosurf) for respiratory distress syndrome. A postmarketing phase IV study.
Lamboley-Gilmert G; Lacaze-Masmonteil T;
Paediatr Drugs; 2003; 5(9):639-45. PubMed ID: 12956620
[TBL] [Abstract][Full Text] [Related]
17. Poractant alfa versus beractant for respiratory distress syndrome in preterm infants: a retrospective cohort study.
Paul S; Rao S; Kohan R; McMichael J; French N; Zhang G; Simmer K
J Paediatr Child Health; 2013 Oct; 49(10):839-44. PubMed ID: 23802801
[TBL] [Abstract][Full Text] [Related]
18. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.
Dizdar EA; Sari FN; Aydemir C; Oguz SS; Erdeve O; Uras N; Dilmen U
Am J Perinatol; 2012 Feb; 29(2):95-100. PubMed ID: 22105435
[TBL] [Abstract][Full Text] [Related]
19. Poractant alfa versus bovine lipid extract surfactant for infants 24+0 to 31+6 weeks gestational age: A randomized controlled trial.
Lemyre B; Fusch C; Schmölzer GM; Rouvinez Bouali N; Reddy D; Barrowman N; Huneault-Purney N; Lacaze-Masmonteil T
PLoS One; 2017; 12(5):e0175922. PubMed ID: 28472058
[TBL] [Abstract][Full Text] [Related]
20. Nebulization of Poractant alfa via a vibrating membrane nebulizer in spontaneously breathing preterm lambs with binasal continuous positive pressure ventilation.
Hütten MC; Kuypers E; Ophelders DR; Nikiforou M; Jellema RK; Niemarkt HJ; Fuchs C; Tservistas M; Razetti R; Bianco F; Kramer BW
Pediatr Res; 2015 Dec; 78(6):664-9. PubMed ID: 26322413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
